Literature DB >> 21145657

Evidence-based clinical trial design for chronic pain pharmacotherapy: a blueprint for ACTION.

Robert H Dworkin1, Dennis C Turk, Nathaniel P Katz, Michael C Rowbotham, Sarah Peirce-Sandner, Igor Cerny, Chekesha S Clingman, Benjamin C Eloff, John T Farrar, Cornelia Kamp, Michael P McDermott, Bob A Rappaport, Wendy R Sanhai.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21145657     DOI: 10.1016/j.pain.2010.11.008

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


× No keyword cloud information.
  22 in total

Review 1.  [Placebo responders in randomized controlled drug trials of fibromyalgia syndrome : Systematic review and meta-analysis].

Authors:  W Häuser; E Bartram-Wunn; C Bartram; T R Tölle
Journal:  Schmerz       Date:  2011-12       Impact factor: 1.107

2.  Assay sensitivity and study features in neuropathic pain trials: an ACTTION meta-analysis.

Authors:  Robert H Dworkin; Dennis C Turk; Sarah Peirce-Sandner; Hua He; Michael P McDermott; John T Farrar; Nathaniel P Katz; Allison H Lin; Bob A Rappaport; Michael C Rowbotham
Journal:  Neurology       Date:  2013-05-22       Impact factor: 9.910

Review 3.  Essential statistical principles of clinical trials of pain treatments.

Authors:  Robert H Dworkin; Scott R Evans; Omar Mbowe; Michael P McDermott
Journal:  Pain Rep       Date:  2020-12-18

Review 4.  Design and conduct of confirmatory chronic pain clinical trials.

Authors:  Nathaniel Katz
Journal:  Pain Rep       Date:  2020-12-18

5.  Experimental comparison of parametric versus nonparametric analyses of data from the cold pressor test.

Authors:  Roi Treister; Christopher S Nielsen; Audun Stubhaug; John T Farrar; Dorit Pud; Shlomo Sawilowsky; Anne Louise Oaklander
Journal:  J Pain       Date:  2015-03-20       Impact factor: 5.820

6.  Current challenges in translational pain research.

Authors:  Jianren Mao
Journal:  Trends Pharmacol Sci       Date:  2012-09-06       Impact factor: 14.819

7.  Physician perspective on incorporation of oncology patient quality-of-life, fatigue, and pain assessment into clinical practice.

Authors:  Joleen M Hubbard; Axel F Grothey; Robert R McWilliams; Jan C Buckner; Jeff A Sloan
Journal:  J Oncol Pract       Date:  2014-03-25       Impact factor: 3.840

Review 8.  What can be done to control the placebo response in clinical trials? A narrative review.

Authors:  Kathryn Evans; Luana Colloca; Marta Pecina; Nathaniel Katz
Journal:  Contemp Clin Trials       Date:  2021-07-06       Impact factor: 2.226

9.  Research design considerations for randomized controlled trials of spinal cord stimulation for pain: Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials/Institute of Neuromodulation/International Neuromodulation Society recommendations.

Authors:  Nathaniel Katz; Robert H Dworkin; Richard North; Simon Thomson; Sam Eldabe; Salim M Hayek; Brian H Kopell; John Markman; Ali Rezai; Rod S Taylor; Dennis C Turk; Eric Buchser; Howard Fields; Gregory Fiore; McKenzie Ferguson; Jennifer Gewandter; Chris Hilker; Roshini Jain; Angela Leitner; John Loeser; Ewan McNicol; Turo Nurmikko; Jane Shipley; Rahul Singh; Andrea Trescot; Robert van Dongen; Lalit Venkatesan
Journal:  Pain       Date:  2021-07-01       Impact factor: 6.961

Review 10.  Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations.

Authors:  Robert R Edwards; Robert H Dworkin; Dennis C Turk; Martin S Angst; Raymond Dionne; Roy Freeman; Per Hansson; Simon Haroutounian; Lars Arendt-Nielsen; Nadine Attal; Ralf Baron; Joanna Brell; Shay Bujanover; Laurie B Burke; Daniel Carr; Amy S Chappell; Penney Cowan; Mila Etropolski; Roger B Fillingim; Jennifer S Gewandter; Nathaniel P Katz; Ernest A Kopecky; John D Markman; George Nomikos; Linda Porter; Bob A Rappaport; Andrew S C Rice; Joseph M Scavone; Joachim Scholz; Lee S Simon; Shannon M Smith; Jeffrey Tobias; Tina Tockarshewsky; Christine Veasley; Mark Versavel; Ajay D Wasan; Warren Wen; David Yarnitsky
Journal:  Pain       Date:  2016-09       Impact factor: 7.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.